Gordh 2008.

Methods	Multicentre, randomised, double‐blind, placebo‐controlled, cross‐over, not enriched. No imputation method mentioned Titration over 2 weeks from 300 mg to maximum pain relief at a tolerable dose or 2400 mg daily, then stable dose for 3 weeks (5 weeks total); 3‐week washout, then cross‐over
Participants	Peripheral nerve injury with pain ≥ 6 months. PI at randomisation > 30/100 N = 120 (efficacy analysis based on 98 who completed both treatment periods) Mean age 49 years, 53% women Initial pain intensity 53/100
Interventions	Gabapentin 2400 mg daily (max) Placebo Mean daily dose of gabapentin 2243 mg ± 402 mg Paracetamol ± codeine and dextropropoxyphene permitted as rescue medication Analgesics and NSAIDs used by ˜ 50% during study
Outcomes	≥ 50% pain relief (weekly mean pain score) ≥ 30% pain relief Marked pain relief (5‐point scale) Marked or moderate pain relief (5‐point scale) Adverse events Withdrawals
Notes	Oxford Quality Score: R = 2, DB = 2, W = 1, Total = 5 Sponsored by Parke‐Davis AB, later Pfizer AB
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation list was generated by the Clinical Pharmaceutical Operation Center in Freiburg
Allocation concealment (selection bias)	Low risk	Central, remote allocation, "sealed code envelope"
Blinding (performance bias and detection bias) All outcomes	Low risk	"capsules that were identical in appearance"
Incomplete outcome data (attrition bias) Efficacy	Unclear risk	Imputation not mentioned
Size Efficacy	Unclear risk	50‐200 participants per treatment arm (98 completed both periods and included in efficacy analysis)